{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:54:33Z","timestamp":1794660873331,"version":"4.9.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess current evidence for effectiveness of sequential lines of biologic and targeted small-molecule disease-modifying anti-rheumatic drugs (b\/tsDMARDs) when used beyond first-line for psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A systematic search of the literature (Medline, Embase, bibliographic searches) was undertaken (October and December 2022) to find studies meeting the criteria of assessing effectiveness of b\/tsDMARDs beyond first-line in adults with PsA (PROSPERO CRD42022365298). Risk of bias assessment was undertaken (ROBINS-I\/Cochrane RoB2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 2666 abstracts identified and following a full text review of 177 psoriatic disease studies, 12 manuscripts and two abstracts were eligible. Of the 12 manuscripts, 11 were observational and one was a sub-analysis of a RCT (n\u2009=\u200916\u2009081: average age 49.5\u2009years, female 53.3%). Two abstracts (n\u2009=\u20097186) were included. All studies comparing first- and second-line (three studies) found a reduced response in second-line. On average, DAPSA remission (most reported outcome, eight studies) was achieved in 26%, 19% and 10% first-, second- and third-line TNFi, and 22%, 13% and 11% first-, second- and third-line other bDMARDs, respectively. Responses varied to third-line bDMARDs; four studies found comparable second- and third-line responses, five studies found diminishing responses in sequential lines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Predominantly observational studies, inherently at high risk of bias, indicate bDMARDs can be effective to third-line in PsA, but that response is reduced after first line. There is very limited data for more advanced lines of b\/tsDMARD. Prospective studies are required to better understand clinical response to advanced lines of treatment in PsA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae006","type":"journal-article","created":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T08:48:00Z","timestamp":1705740480000},"page":"1790-1802","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of sequential lines of biologic and targeted small-molecule drugs in psoriatic arthritis: a systematic review"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7539-4265","authenticated-orcid":false,"given":"Charlotte E","family":"Gollins","sequence":"first","affiliation":[{"name":"Department of Dermatology, Royal United Hospitals Bath NHS Foundation Trust , Bath, UK"},{"name":"Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3559-6356","authenticated-orcid":false,"given":"Rosie","family":"Vincent","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospitals Bristol and Weston NHS Foundation Trust , Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caoimhe","family":"Fahy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Royal United Hospitals Bath NHS Foundation Trust , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"McHugh","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mel","family":"Brooke","sequence":"additional","affiliation":[{"name":"British Psoriatic Arthritis Consortium (BritPACT), Bath Institute for Rheumatic Diseases, Royal United Hospital , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath , Bath, UK"},{"name":"Royal National Hospital for Rheumatic Diseases , Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"2024070114110085800_keae006-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2024070114110085800_keae006-B2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2024070114110085800_keae006-B3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11926-012-0263-5","article-title":"Impact of psoriatic arthritis on the patient: through the lens of the who international classification of functioning, health, and disability","volume":"14","author":"Taylor","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"2024070114110085800_keae006-B4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/rheumatology\/keu264","article-title":"Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study","volume":"54","author":"Tillett","year":"2015","journal-title":"Rheumatology"},{"key":"2024070114110085800_keae006-B5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/rheumatology\/ker216","article-title":"Work disability in psoriatic arthritis: a systematic review","volume":"51","author":"Tillett","year":"2012","journal-title":"Rheumatology"},{"key":"2024070114110085800_keae006-B6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Exp Rev Clin Immunol"},{"key":"2024070114110085800_keae006-B7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"New Engl J Med"},{"key":"2024070114110085800_keae006-B8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024070114110085800_keae006-B9","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s40744-022-00461-w","article-title":"Clinical characteristics of potential \u201cDifficult-to-treat\u201d patients with psoriatic arthritis: a retrospective analysis of a longitudinal cohort","volume":"9","author":"Perrotta","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2024070114110085800_keae006-B10","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10067-017-3593-x","article-title":"Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry","volume":"36","author":"Harrold","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2024070114110085800_keae006-B11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/rheumatology\/kex387","article-title":"Prevalence and predictors of tumour necrosis factor inhibitor persistence in psoriatic arthritis","volume":"57","author":"Stober","year":"2018","journal-title":"Rheumatology"},{"key":"2024070114110085800_keae006-B12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/jid.2015.171","article-title":"Drug survival studies in dermatology: principles, purposes, and pitfalls","volume":"135","author":"van den Reek","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2024070114110085800_keae006-B13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2024070114110085800_keae006-B14","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s10067-016-3425-4","article-title":"Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature","volume":"35","author":"Reddy","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2024070114110085800_keae006-B15","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s40744-021-00337-5","article-title":"Secukinumab efficacy on psoriatic arthritis GRAPPA-OMERACT core domains in patients with or without prior tumor necrosis factor inhibitor use: pooled analysis of four phase 3 studies","volume":"8","author":"Orbai","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2024070114110085800_keae006-B16","doi-asserted-by":"crossref","first-page":"e14336","DOI":"10.1111\/dth.14336","article-title":"Retrospective analysis of patients with psoriasis receiving biological therapy: real-life data","volume":"33","author":"\u00d6z\u00e7elik","year":"2020","journal-title":"Dermatol Ther"},{"key":"2024070114110085800_keae006-B17","doi-asserted-by":"crossref","first-page":"e952","DOI":"10.1111\/jdv.18381","article-title":"Real-life intraclass switch among IL-17 inhibitors in psoriasis: results from a single-centre, 24-week, Retrospective study","volume":"36","author":"Sotiriou","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024070114110085800_keae006-B18","doi-asserted-by":"crossref","first-page":"e15757","DOI":"10.1111\/dth.15757","article-title":"Ustekinumab to guselkumab transitions: a series of 54 patients emulating the navigate trial in real life","volume":"35","author":"Berenguer-Ruiz","year":"2022","journal-title":"Dermatol Ther"},{"key":"2024070114110085800_keae006-B19","doi-asserted-by":"crossref","first-page":"789.2","DOI":"10.1136\/annrheumdis-2021-eular.659","article-title":"Response to sequential lines of biological therapy in psoriatic arthritis: a single centre cohort study. Annals of the Rheumatic Diseases Conference: European Congress of Rheumatology, EULAR 2021 Jun 2-5. Virtual","volume":"80","author":"Abdalla","journal-title":"Ann Rheum Dis"},{"key":"2024070114110085800_keae006-B20","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2024070114110085800_keae006-B21","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.3","author":"Sterne","year":"2022"},{"key":"2024070114110085800_keae006-B22","volume-title":"Cochrane handbook for systematic reviews of interventions version 6.3","author":"Higgins","year":"2022"},{"key":"2024070114110085800_keae006-B23","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.3390\/jcm11144178","article-title":"Effectiveness of golimumab as second anti-TNFalpha drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective real-world observational study","volume":"11","author":"D'Angelo","year":"2022","journal-title":"J Clin Med"},{"key":"2024070114110085800_keae006-B24","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024070114110085800_keae006-B25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00296-019-04416-3","article-title":"Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort","volume":"40","author":"Favalli","year":"2020","journal-title":"Rheumatol Int"},{"key":"2024070114110085800_keae006-B26","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024070114110085800_keae006-B27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from southern Sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"J Rheumatol"},{"key":"2024070114110085800_keae006-B28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40744-020-00204-9","article-title":"Golimumab as the first-, second-, or at least third-line biologic agent in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis: post hoc analysis of a noninterventional study in Germany","volume":"7","author":"Kruger","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2024070114110085800_keae006-B29","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1093\/rheumatology\/keaa825","article-title":"Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis","volume":"60","author":"Lindstrom","year":"2021","journal-title":"Rheumatology"},{"key":"2024070114110085800_keae006-B30","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40744-022-00446-9","article-title":"Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the Spanish BIOBADASER Registry","volume":"9","author":"Moreno-Ramos","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2024070114110085800_keae006-B31","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/annrheumdis-2021-220263","article-title":"Effectiveness of IL-12\/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results","volume":"80","author":"Smolen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024070114110085800_keae006-B32","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3899\/jrheum.181272","article-title":"Real-world long term effectiveness of tumor necrosis factor inhibitors in psoriatic arthritis patients from the rheumatic diseases Portuguese register","volume":"47","author":"Vieira-Sousa","year":"2020","journal-title":"J Rheumatol"},{"key":"2024070114110085800_keae006-B33","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/acr.24560","article-title":"Real-world six- and twelve-month drug retention, remission, and response rates of secukinumab in 2,017 patients with psoriatic arthritis in thirteen European countries","volume":"74","author":"Michelsen","year":"2022","journal-title":"Arthritis Care Res"},{"key":"2024070114110085800_keae006-B34","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024070114110085800_keae006-B35","first-page":"1401","article-title":"Does drug effectiveness of 2nd and 3rd tnf inhibitors in patients with psoriatic arthritis depend on the reason for withdrawal from the previous treatment? Results from the Eurospa research collaboration. The Rheumatic Diseases Conference: European Congress of Rheumatology, EULAR 2019 Jun 12-15. Madrid, Spain","volume":"78(Suppl 2)","author":"Brahe","journal-title":"Ann Rheum Dis"},{"key":"2024070114110085800_keae006-B36","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2665-9913(21)00349-0","article-title":"The state of the art\u2014psoriatic arthritis outcome assessment in clinical trials and daily practice","volume":"4","author":"Day","year":"2022","journal-title":"Lancet Rheum"},{"key":"2024070114110085800_keae006-B37","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/annrheumdis-2020-216999","article-title":"Use of multidimensional composite scores in rheumatology: parsimony versus subtlety","volume":"80","author":"Landew\u00e9","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2024070114110085800_keae006-B38","first-page":"2098","article-title":"Nociplastic pain: towards an understanding of prevalent pain conditions","volume":"397","author":"Fitzcharles","year":"2021","journal-title":"Lancet (British edition)"},{"key":"2024070114110085800_keae006-B39","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.6061\/clinics\/2021\/e3015","article-title":"Immunogenicity to biological drugs in psoriasis and psoriatic arthritis","volume":"76","author":"Valenzuela","year":"2021","journal-title":"Clinics (S\u00e3o Paulo)"},{"key":"2024070114110085800_keae006-B40","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s40265-018-0898-2","article-title":"Role of methotrexate in the management of psoriatic arthritis","volume":"78","author":"Elmamoun","year":"2018","journal-title":"Drugs"},{"key":"2024070114110085800_keae006-B41","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/art.21570","article-title":"The LUNDEX, a new index of drug efficacy in clinical practice","volume":"54","author":"Kristensen","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae006\/56533224\/keae006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/7\/1790\/58378475\/keae006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/7\/1790\/58378475\/keae006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T18:07:37Z","timestamp":1719857257000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/7\/1790\/7577853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,1,18]]},"published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae006","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7]]},"published":{"date-parts":[[2024,1,18]]}}}